The EC has approved Alnylam Pharmaceuticals' Amvuttra (vutrisiran) to treat wild-type or hereditary ATTR-CM in adults.

Climbing stairs is a powerful fitness test. Here's how many flights show you’re in peak shape—no equipment required.

ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.

The speed at which you walk can reveal profound insights into your brain's rate of ageing – with slower walkers having smaller brains and fundamental differences in crucial structures.

This study presents an intrinsic capacity clock, using blood samples to predict mortality risk and enhance understanding of ...

A team of international researchers has developed a new biological age "clock" that estimates how well someone is aging, not ...

Skipping breakfast chronically disrupts circadian rhythms, elevates stress hormones, and damages blood sugar control over ...

In PAH, 5-year mortality is similar with and without obesity, even though patients with obesity have more comorbidities and worse functional capacity.

American women now average 170 pounds at 5'3" height. Discover how age, lifestyle, and health factors influence weight beyond ...

Avio Health Agentic AI Avio Health uses Agentic AI to predict healthspan by analyzing labs, records, and lifestyle-turning complex d ...

Did you know that immersing your body in natural water can boost your cardiovascular health more effectively than some ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild ...